Skip to main content
SpringerLink
Log in

Healed Myocardial Infarction

  • Chapter
  • First Online:
Coronary Heart Disease

  • 2671 Accesses

Abstract

Among the many devastating complications of healed myocardial infarction is heart failure (HF). Despite its ubiquitous role in causing death and disability around the globe, HF is quite difficult to define. It has a great deal of heterogeneity, can be acute or chronic, may involve primarily the left ventricle or right ventricle (or both), can be associated with a low or normal left ventricular ejection fraction (LVEF), and has numerous causes. This chapter focuses on HF due to chronic coronary artery disease (CAD).

Virtually any form of heart disease can lead to heart failure. In general, HF is a clinical syndrome caused by structural and/or functional changes in the heart that lead to dyspnea, fatigue, and in many cases, salt and water retention. Comorbidities such as CAD, hypertension, diabetes mellitus, chronic kidney disease, or atrial fibrillation frequently accompany HF, and may contribute to or aggravate the HF syndrome.

In the end, patients typically become gradually more and more disabled and eventually die prematurely from pump dysfunction or arrhythmia. Improvement in therapy the past 30 years has improved survival, but HF continues to exact a toll on patients, their families, and the worldwide economy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Felker GM, Shaw LK, O’Conner CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210–8.

    Article  PubMed  Google Scholar 

  2. Bart BA, Shaw LK, McCants CB, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30:1002–8.

    Article  PubMed  CAS  Google Scholar 

  3. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 1987;59:634–8.

    Article  PubMed  CAS  Google Scholar 

  4. Farb A, Tang AL, Burke AP, et al. Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 1995;92:1701–9.

    Article  PubMed  CAS  Google Scholar 

  5. Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996;28:1781–8.

    Article  PubMed  Google Scholar 

  6. Tavazzi L. Towards a more precise definition of heart failure aetiology. Eur J Cardiol. 2002;22:192–5.

    Article  Google Scholar 

  7. Kannel WB, Ho K, Thom K. Changing epidemiological features of cardiac failure. Eur Heart J. 1994;72(Suppl):S3–9.

    CAS  Google Scholar 

  8. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–62.

    Article  PubMed  CAS  Google Scholar 

  9. Fox C, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus. The Framingham heart study. Circulation. 2007;115:1544–50.

    Article  PubMed  Google Scholar 

  10. Braunwald E, Rutherford J. Reversible ischemic left ventricular dysfunction: evidence of the “hibernating myocardium”. J Am Coll Cardiol. 1986;8:1467–70.

    Article  PubMed  CAS  Google Scholar 

  11. Underwood SR, Bax JJ, vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Eur Heart J. 2004;25:815–36.

    Article  PubMed  Google Scholar 

  12. Gheoghiade M, Sopko G, DeLuca L, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114:1202–13.

    Article  Google Scholar 

  13. Cohn J, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569–82.

    Article  PubMed  CAS  Google Scholar 

  14. Solomon SD, Skali H, Anavekar NS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril or both after myocardial infarction. Circulation. 2005;111:3411–9.

    Article  PubMed  CAS  Google Scholar 

  15. Cheong BYC, Muthupillai R, Wilson JM, et al. Prognostic significance of delayed-enhancement magnetic resonance imaging. Survival of 857 patients with and without left ventricular dysfunction. Circulation. 2009;120:2069–76.

    Article  PubMed  Google Scholar 

  16. Uretsky BF, Thygesen K, Armstrong P, et al. Acute coronary findings at autopsy in heart failure patients with sudden death. Results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;102:611–6.

    Article  PubMed  CAS  Google Scholar 

  17. Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease. Early assessment and treatment. J Am Coll Cardiol. 2009;53:254–63.

    Article  PubMed  Google Scholar 

  18. Goldberg RJ, Ciampa J, Lessard D, et al. Long-term survival after heart failure: a contemporary population based perspective. Arch Intern Med. 2007;167:490–6.

    Article  PubMed  Google Scholar 

  19. Zile M, Brutsaert D. New concepts in diastolic dysfunction and diastolic heart failure: Part 1. Diagnosis, prognosis, and measurement of diastolic function. Circulation. 2002;105:1387–93.

    Article  PubMed  Google Scholar 

  20. Chatterjee K, Massie B. Systolic and diastolic heart failure: differences and similarities. J Card Fail. 2007;13:569–76.

    Article  PubMed  Google Scholar 

  21. Dauterman KW, Go AS, Rowell R, et al. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail. 2001;7:221–8.

    Article  PubMed  CAS  Google Scholar 

  22. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777–81.

    Article  PubMed  CAS  Google Scholar 

  23. Cleland JG, Tendera M, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.

    Article  PubMed  CAS  Google Scholar 

  24. Cleland JGF, Daubert J-C, Erdmann E, et al., on behalf of the CARE-CHF Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.

    Google Scholar 

  25. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.

    Article  PubMed  CAS  Google Scholar 

  26. Epstein AE, DiMarco JP, Ellebogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol. 2008;51:e1–62.

    Article  PubMed  Google Scholar 

  27. Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002;105:438–45.

    Article  PubMed  Google Scholar 

  28. St. John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985–90.

    Article  PubMed  Google Scholar 

  29. Cleland J, Freemantle N, Ghio S, et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response. A report from the CARE-CHF (Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Cardiol. 2008;52:438–45.

    Article  PubMed  Google Scholar 

  30. Marwick TH. Hype and hope in the use of echocardiography for selection for cardiac resynchronization therapy. The Tower of Babel revisited. Circulation. 2008;117:2573–6.

    Article  PubMed  Google Scholar 

  31. Moss AJ, Hall WJ, Cannom DS, et al., for the MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.

    Google Scholar 

  32. Linde C, Abraham WT, Gold MR, St. John Sutton M, Ghio S, Daybert C, on behalf of the REVERSE Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Coll Cardiol. 2008;52:1834–43.

    Google Scholar 

  33. St. John Sutton M, Ghio S, Plappert T, et al., on behalf of the REVERSE Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009;120:1858–65.

    Google Scholar 

  34. Francis GS, Tang WHW. Early cardiac resynchronization therapy and reverse remodeling in patients with mild heart failure. Is it time? Circulation. 2009;120:1845–6.

    Article  PubMed  Google Scholar 

  35. Daubert C, Gold MR, Abraham WT, et al., on behalf of the REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. J Am Coll Cardiol. 2009;54:1837–46.

    Google Scholar 

  36. Stratton JR, Nemanich JW, Johannessem K-A, Resnick AD. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation. 1998;78:1388–93.

    Article  Google Scholar 

  37. Freudenberger RS, Hellkamp AS, Halpern JL, et al., for the SCD-HeFT Investigators. Risk of thromboembolism in heart failure. An analysis from Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2008;115:2637–41.

    Google Scholar 

  38. Massie B, Cillins JF, Ammon SE, et al., for the WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure. The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119:1616–24.

    Google Scholar 

  39. Vargas SO, Sampson BA, Schoen FJ. Pathological detection of early myocardial infarction: a critical review of the evolution and usefulness of modern techniques. Mod Pathol. 1999;12:635–45.

    PubMed  CAS  Google Scholar 

  40. Abildstrom SZ, Ottesen MM, Rask-Madsen C, et al. Sudden cardiovascular death following myocardial infarction: the importance of left ventricular systolic dysfunction and congestive heart failure. Int J Cardiol. 2005;104:184–9.

    Article  PubMed  Google Scholar 

  41. Verma S, Mesana TG. Mitral valve repair for mitral-valve prolapse. N Engl J Med. 2009;361:2261–9.

    Article  PubMed  CAS  Google Scholar 

  42. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161–72.

    Article  PubMed  CAS  Google Scholar 

  43. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005;352:875–83.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, University of Minnesota, 420 Delaware Ave S.E, Minneapolis, MN, 55455, USA

    Gary S. Francis MD

  2. Division of Cardiovascular Medicine, University of Minnesota, Minneapolis, MN, USA

    Daniel J. Garry MD, PhD

Authors
  1. Gary S. Francis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel J. Garry MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary S. Francis MD .

Editor information

Editors and Affiliations

  1. Edgcumbe Place 6, St. Paul, 55116, Minnesota, USA

    Zeev Vlodaver

  2. University of Minnesota, Delaware Street S.E. 420, Minneapolis, 55455, Minnesota, USA

    Robert F. Wilson

  3. 4-112 Nils Hasselmo Hall, University of Minnesota, Church Street S.E. 312, Minneapolis, 55455, Minnesota, USA

    Daniel J. Garry

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Francis, G.S., Garry, D.J. (2012). Healed Myocardial Infarction. In: Vlodaver, Z., Wilson, R., Garry, D. (eds) Coronary Heart Disease. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-1475-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1475-9_19

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-1474-2

  • Online ISBN: 978-1-4614-1475-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation